Natalizumab (Tysabri)

Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanis...

Full description

Saved in:
Bibliographic Details
Published in:American journal of neuroradiology : AJNR 2010-10, Vol.31 (9), p.1588-1590
Main Authors: SELEWSKI, D. T, SHAH, G. V, SEGAL, B. M, RAJDEV, P. A, MUKHERJI, S. K
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Brain - drug effects
Brain - immunology
Cell Adhesion - drug effects
Cell Adhesion - immunology
Cell Migration Inhibition - drug effects
Cell Migration Inhibition - immunology
Humans
Investigative techniques, diagnostic techniques (general aspects)
Leukocytes - drug effects
Leukocytes - immunology
Medical sciences
Models, Immunological
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
Natalizumab
Nervous system
Pharmacology Vignette
Radiodiagnosis. Nmr imagery. Nmr spectrometry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c464t-d31c97a782b3203b45309b92ce4932584725ef7dcc6c45d846545b7f20b7a32d3
cites cdi_FETCH-LOGICAL-c464t-d31c97a782b3203b45309b92ce4932584725ef7dcc6c45d846545b7f20b7a32d3
container_end_page 1590
container_issue 9
container_start_page 1588
container_title American journal of neuroradiology : AJNR
container_volume 31
creator SELEWSKI, D. T
SHAH, G. V
SEGAL, B. M
RAJDEV, P. A
MUKHERJI, S. K
description Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
doi_str_mv 10.3174/ajnr.A2226
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7964985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>757459221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-d31c97a782b3203b45309b92ce4932584725ef7dcc6c45d846545b7f20b7a32d3</originalsourceid><addsrcrecordid>eNqFkElLA0EQRhtRTIxeBK_iRVxgYu_LRQjBDYJeInhrunt6dMIs2j0jxF_vxMSoJ-tSh3p81PcA2EdwSJCgF2ZWheEIY8w3QB8pwhPF1NMm6EOkWMIRlD2wE-MMQsiUwNughyGX3ag-OLg3jSnyj7Y09uh0Oo_GhvxsF2xlpoh-b7UH4PH6ajq-TSYPN3fj0SRxlNMmSQlyShghsSUYEksZgcoq7DxVBDNJBWY-E6lz3FGWSsoZZVZkGFphCE7JAFwuc19bW_rU-aoJptCvIS9NmOva5Prvpcpf9HP9roXiVEnWBZysAkL91vrY6DKPzheFqXzdRi0l6SQQhv8lBROUKYxRR54vSRfqGIPP1v8gqBfC9UK4_hLewYe_G6zRb8MdcLwCTHSmyIKpXB5_OIIXVRT5BA9-hxM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>757459221</pqid></control><display><type>article</type><title>Natalizumab (Tysabri)</title><source>PubMed Central</source><creator>SELEWSKI, D. T ; SHAH, G. V ; SEGAL, B. M ; RAJDEV, P. A ; MUKHERJI, S. K</creator><creatorcontrib>SELEWSKI, D. T ; SHAH, G. V ; SEGAL, B. M ; RAJDEV, P. A ; MUKHERJI, S. K</creatorcontrib><description>Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.</description><identifier>ISSN: 0195-6108</identifier><identifier>EISSN: 1936-959X</identifier><identifier>DOI: 10.3174/ajnr.A2226</identifier><identifier>PMID: 20688889</identifier><identifier>CODEN: AAJNDL</identifier><language>eng</language><publisher>Oak Brook, IL: American Society of Neuroradiology</publisher><subject>Animals ; Antibodies, Monoclonal - administration &amp; dosage ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal, Humanized ; Biological and medical sciences ; Brain - drug effects ; Brain - immunology ; Cell Adhesion - drug effects ; Cell Adhesion - immunology ; Cell Migration Inhibition - drug effects ; Cell Migration Inhibition - immunology ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Leukocytes - drug effects ; Leukocytes - immunology ; Medical sciences ; Models, Immunological ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - immunology ; Natalizumab ; Nervous system ; Pharmacology Vignette ; Radiodiagnosis. Nmr imagery. Nmr spectrometry</subject><ispartof>American journal of neuroradiology : AJNR, 2010-10, Vol.31 (9), p.1588-1590</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © American Society of Neuroradiology 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-d31c97a782b3203b45309b92ce4932584725ef7dcc6c45d846545b7f20b7a32d3</citedby><cites>FETCH-LOGICAL-c464t-d31c97a782b3203b45309b92ce4932584725ef7dcc6c45d846545b7f20b7a32d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7964985/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7964985/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23296499$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20688889$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SELEWSKI, D. T</creatorcontrib><creatorcontrib>SHAH, G. V</creatorcontrib><creatorcontrib>SEGAL, B. M</creatorcontrib><creatorcontrib>RAJDEV, P. A</creatorcontrib><creatorcontrib>MUKHERJI, S. K</creatorcontrib><title>Natalizumab (Tysabri)</title><title>American journal of neuroradiology : AJNR</title><addtitle>AJNR Am J Neuroradiol</addtitle><description>Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - administration &amp; dosage</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - immunology</subject><subject>Cell Adhesion - drug effects</subject><subject>Cell Adhesion - immunology</subject><subject>Cell Migration Inhibition - drug effects</subject><subject>Cell Migration Inhibition - immunology</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Leukocytes - drug effects</subject><subject>Leukocytes - immunology</subject><subject>Medical sciences</subject><subject>Models, Immunological</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - immunology</subject><subject>Natalizumab</subject><subject>Nervous system</subject><subject>Pharmacology Vignette</subject><subject>Radiodiagnosis. Nmr imagery. Nmr spectrometry</subject><issn>0195-6108</issn><issn>1936-959X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqFkElLA0EQRhtRTIxeBK_iRVxgYu_LRQjBDYJeInhrunt6dMIs2j0jxF_vxMSoJ-tSh3p81PcA2EdwSJCgF2ZWheEIY8w3QB8pwhPF1NMm6EOkWMIRlD2wE-MMQsiUwNughyGX3ag-OLg3jSnyj7Y09uh0Oo_GhvxsF2xlpoh-b7UH4PH6ajq-TSYPN3fj0SRxlNMmSQlyShghsSUYEksZgcoq7DxVBDNJBWY-E6lz3FGWSsoZZVZkGFphCE7JAFwuc19bW_rU-aoJptCvIS9NmOva5Prvpcpf9HP9roXiVEnWBZysAkL91vrY6DKPzheFqXzdRi0l6SQQhv8lBROUKYxRR54vSRfqGIPP1v8gqBfC9UK4_hLewYe_G6zRb8MdcLwCTHSmyIKpXB5_OIIXVRT5BA9-hxM</recordid><startdate>20101001</startdate><enddate>20101001</enddate><creator>SELEWSKI, D. T</creator><creator>SHAH, G. V</creator><creator>SEGAL, B. M</creator><creator>RAJDEV, P. A</creator><creator>MUKHERJI, S. K</creator><general>American Society of Neuroradiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20101001</creationdate><title>Natalizumab (Tysabri)</title><author>SELEWSKI, D. T ; SHAH, G. V ; SEGAL, B. M ; RAJDEV, P. A ; MUKHERJI, S. K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-d31c97a782b3203b45309b92ce4932584725ef7dcc6c45d846545b7f20b7a32d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - administration &amp; dosage</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - immunology</topic><topic>Cell Adhesion - drug effects</topic><topic>Cell Adhesion - immunology</topic><topic>Cell Migration Inhibition - drug effects</topic><topic>Cell Migration Inhibition - immunology</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Leukocytes - drug effects</topic><topic>Leukocytes - immunology</topic><topic>Medical sciences</topic><topic>Models, Immunological</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - immunology</topic><topic>Natalizumab</topic><topic>Nervous system</topic><topic>Pharmacology Vignette</topic><topic>Radiodiagnosis. Nmr imagery. Nmr spectrometry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SELEWSKI, D. T</creatorcontrib><creatorcontrib>SHAH, G. V</creatorcontrib><creatorcontrib>SEGAL, B. M</creatorcontrib><creatorcontrib>RAJDEV, P. A</creatorcontrib><creatorcontrib>MUKHERJI, S. K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of neuroradiology : AJNR</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SELEWSKI, D. T</au><au>SHAH, G. V</au><au>SEGAL, B. M</au><au>RAJDEV, P. A</au><au>MUKHERJI, S. K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natalizumab (Tysabri)</atitle><jtitle>American journal of neuroradiology : AJNR</jtitle><addtitle>AJNR Am J Neuroradiol</addtitle><date>2010-10-01</date><risdate>2010</risdate><volume>31</volume><issue>9</issue><spage>1588</spage><epage>1590</epage><pages>1588-1590</pages><issn>0195-6108</issn><eissn>1936-959X</eissn><coden>AAJNDL</coden><abstract>Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.</abstract><cop>Oak Brook, IL</cop><pub>American Society of Neuroradiology</pub><pmid>20688889</pmid><doi>10.3174/ajnr.A2226</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-6108
ispartof American journal of neuroradiology : AJNR, 2010-10, Vol.31 (9), p.1588-1590
issn 0195-6108
1936-959X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7964985
source PubMed Central
subjects Animals
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal, Humanized
Biological and medical sciences
Brain - drug effects
Brain - immunology
Cell Adhesion - drug effects
Cell Adhesion - immunology
Cell Migration Inhibition - drug effects
Cell Migration Inhibition - immunology
Humans
Investigative techniques, diagnostic techniques (general aspects)
Leukocytes - drug effects
Leukocytes - immunology
Medical sciences
Models, Immunological
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
Natalizumab
Nervous system
Pharmacology Vignette
Radiodiagnosis. Nmr imagery. Nmr spectrometry
title Natalizumab (Tysabri)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A13%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natalizumab%20(Tysabri)&rft.jtitle=American%20journal%20of%20neuroradiology%20:%20AJNR&rft.au=SELEWSKI,%20D.%20T&rft.date=2010-10-01&rft.volume=31&rft.issue=9&rft.spage=1588&rft.epage=1590&rft.pages=1588-1590&rft.issn=0195-6108&rft.eissn=1936-959X&rft.coden=AAJNDL&rft_id=info:doi/10.3174/ajnr.A2226&rft_dat=%3Cproquest_pubme%3E757459221%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c464t-d31c97a782b3203b45309b92ce4932584725ef7dcc6c45d846545b7f20b7a32d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=757459221&rft_id=info:pmid/20688889&rfr_iscdi=true